MedDataX Logo

Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification

NCT ID: NCT01158066

Last Updated: 2011-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Coronary artery disease are 8 times more prevalent in patients with NAFLD then the general population and are being considered the most common cause of death. Cardiac CT is a reliable non invasive method in demonstrating Coronary Plaques. However the association between coronary artery calcium score (CAC) and NAFLD remains controversial

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease

NCT03307408

Hepatocellular Carcinoma
UNKNOWN

Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With NAFLD

NCT04774302

NAFLD
COMPLETED

Fatty Liver in Inflammatory Bowel Disease (IBD) Patients

NCT00855907

Inflammatory Bowel Disease Fatty Liver
TERMINATED

Early Detection of Advanced Fatty Liver Disease

NCT03608748

Non-alcoholic Fatty Liver Disease Liver Fibrosis
COMPLETED

NASH and Coronary Disease

NCT03819283

Non-Alcoholic Fatty Liver Disease
UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Coronary artery disease are 8 times more prevalent in patients with NAFLD that the general population and are being considered the most common cause of death. Cardiac CT is a reliable non invasive method in demonstrating Coronary Plaques. However the association between coronary artery calcium score (CAC) and NAFLD remains controversial. AIM: the aim is to evaluate the association between CAC score ( CT) and NAFLD (CT). the working hypothesis is that Beside the traditional risk factors including age, diabetes, NAFLD is also associated with moderate to high risk of CAD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Calcification

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CT cardiac

the patient will undergo cardiac CT

Group Type NO_INTERVENTION

CT Cardiac

Intervention Type PROCEDURE

the patient will undergo cardiac CT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CT Cardiac

the patient will undergo cardiac CT

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who will undergo cardiac CT for patients with low to intermediate risk for CAD

Exclusion Criteria

* Patients with PCI or CABG will be excluded
Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ziv Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ziv medical center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ziv medical center liver unit

Safed, Israel, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Assy Nimer, MD

Role: CONTACT

[email protected]
+97246828445

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nimer Assy, MD

Role: primary

[email protected]
+972-46828445

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NAFLD and CAC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Relationship Between Fatty Liver and Breast Cancer
NCT06402084 RECRUITING
Macrophage-mediated Inflammation in White Adipose Tissue and Non-alcoholic Fatty Liver Disease.
NCT04059068 COMPLETED
NAFLD in Patient of Hypothyroidism
NCT05813301 NOT_YET_RECRUITING
Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy
NCT01100398 COMPLETED
Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome
NCT00399932 UNKNOWN
Prevalence, Clinical Features and Risk Factors of Cirrhotic Cardiomyopathy Assessed by Two-dimensional Speckle Tracking Imaging
NCT04969055 UNKNOWN
C1q/TNF-related Proteins in Non-Alcoholic Fatty Liver Disease
NCT02083159 UNKNOWN
Fatty Liver and Ectopic Fat in Overweight and Obese Patients
NCT00886301 COMPLETED NA
Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes
NCT06456970 NOT_YET_RECRUITING
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
NCT06814600 RECRUITING
Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)
NCT04191044 UNKNOWN
Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
NCT01324414 COMPLETED
Burden Fatty Liver Among Acute Ischemic Cerebral Stroke Patients
NCT06628700 NOT_YET_RECRUITING
Clinical, Biochemical and Body Composition Analysis in Assessment of Steatosis in Non Alcoholic Fatty Liver Disease
NCT04946786 UNKNOWN
NASH: Non-invasive Diagnostic Markers and Imaging
NCT02717000 UNKNOWN
Examination the Ability to Early Diagnose HCC by Combining Three Biomarkers Technology Developed by WAKO, And Their Relevance to Cirrhotic of Patients With Various Backgrounds and the Israeli Population.
NCT02826005 UNKNOWN NA
Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma
NCT03129685 UNKNOWN NA
Metabolic Dysfunction-Associated Fatty Liver Disease Impairs Intraoperative Indocyanine Green Fluorescence Cholangiography Quality: Development and Validation of a Predictive Model
NCT07297225 COMPLETED
NAFLD Primary Care
NCT04918732 RECRUITING NA
Prospective Cohort Study in Patients With NAFLD
NCT00575133 RECRUITING
Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique
NCT00172705 UNKNOWN
Is There an Association Between Quadriceps Strength and Different Markers of Fragility in Patients With Cirrhosis?
NCT06133127 RECRUITING NA
Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease
NCT01638832 UNKNOWN NA
Correlation Between NAFLD, Epicardial Adipose Tissue and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)
NCT01958411 COMPLETED
Positive Association of US-FLI With the Severity of CAD
NCT06541132 RECRUITING